Evidence map›Paper›PMID 40208335›Full record

ArticleCancer immunology, immunotherapy : CII2025

SIRPα + CD209 + cell: a specialized antigen-presenting cell that contributes to anti-SIRPα/RT therapy in colorectal cancer.

Yida Li, Weiqing Lu, Fan Xia, Yun Deng, Xin Jin, Yan Xuan, Yaqi Wang, Lijun Shen, Juefeng Wan, Hui Zhang and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yida Li *Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Weiqing LuDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Fan Xia *Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Yun DengDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Xin JinDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Yan XuanDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Yaqi WangDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Lijun ShenDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Juefeng WanDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Hui ZhangDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Yaqi LiDepartment of Radiation Oncology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, Jiangsu, China.
Xinxiang LiDepartment of Radiation Oncology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, Jiangsu, China.
Lili HuangDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. huangll_@fudan.edu.cn.
Zhen ZhangDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. Zhen_zhang@fudan.edu.cn.

Funding

National Key Research and Development Program of China 2022YFC2503700
6 · The paper itself

Abstract

objectiveColorectal cancer (CRC) is a leading cause of cancer-related mortality, with a need for improved treatment strategies. Antigen-presenting cells (APCs) have emerged as important modulators of immune responses in the tumor microenvironment (TME). This study aimed to explore the role of these cells in CRC and their potential synergy with radiation therapy (RT).

methodsSingle-cell sequencing was performed before and after neoadjuvant therapy (NAT) to identify changes in myeloid cells within the tumor microenvironment, which was compared with peripheral blood of the same patients. The effect of RT with/without immunotherapy on these cells was evaluated in vivo and in vitro.

resultsSingle-cell sequencing showed that SIRPα + CD209 + cells are specialized antigen-presenting cells which are found to decrease in the TME while increasing in the peripheral blood after NAT. In vitro study confirmed their resistance to RT with further upregulated SIRPα expression and enhanced antigen presentation capability induced by RT. Moreover, these cells are involved in the superior tumor control by combination of RT and anti-SIRPα treatment.

conclusionSIRPα + CD209 + APCs play a pivotal role in CRC immune modulation and show potential for synergy with RT. These cells could be a biomarker for antigen-presenting capacity, and enhancing their APC function could potentially improve RT/PD1 effectiveness by combination with anti-SIRPα in CRC.

Indexed as

Antigen-Presenting CellsAntigens, CDAntigens, DifferentiationColorectal NeoplasmsLectins, C-TypeReceptors, Cell SurfaceReceptors, ImmunologicAnimalsFemaleHumansImmunotherapyMaleMiceTumor MicroenvironmentAntigens, CDAntigens, DifferentiationLectins, C-TypeReceptors, Cell SurfaceReceptors, ImmunologicSIRPA protein, humanAntigen-presenting cellsCD209Colorectal cancerRadiation therapySingle-cell sequencingSIRPα

Identifiers

PMID40208335
PMCPMC11985876

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.